883564-93-0 Usage
Classification
Carboxylic acid
It is an organic compound with a carboxyl functional group (-COOH).
3,6,9,12-tetraoxatetradecane backbone
A 14-carbon chain with four oxygen atoms inserted in the 3rd, 6th, 9th, and 12th positions.
13,13-dimethyl-11-oxo functional group
A functional group consisting of two methyl groups attached to the 13th carbon and an oxo group (double-bonded oxygen) at the 11th position.
Potential applications
Pharmaceutical and agricultural industries
The unique chemical properties of this compound may make it useful in the development of new drugs or agricultural chemicals.
Research status
Further research needed
More studies are required to fully understand the potential uses and implications of this compound.
Check Digit Verification of cas no
The CAS Registry Mumber 883564-93-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,3,5,6 and 4 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 883564-93:
(8*8)+(7*8)+(6*3)+(5*5)+(4*6)+(3*4)+(2*9)+(1*3)=220
220 % 10 = 0
So 883564-93-0 is a valid CAS Registry Number.
883564-93-0Relevant articles and documents
IRAK DEGRADERS AND USES THEREOF
-
, (2020/06/19)
The present invention provides compounds, compositions thereof, and methods of using the same.
TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE
-
Paragraph 1500, (2018/05/24)
The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.
